secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0000950170-23-006282
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eliem restructures, pauses ETX-155, focuses on Kv7 program, extends cash runway into 2027
--------------------------------------------------------------------------------

- Corporate reorganization: pause ETX-155 (GABA A PAM) development, focus on Kv7 program lead ETX-123; workforce reduction ~55% in H1 2023.
- Andrew Levin appointed Executive Chairman after CEO Bob Azelby departure; Dr. Valerie Morisset continues as EVP R&D and CSO.
- Cash, cash equivalents and marketable securities $123.6M as of Dec 31, 2022; expected to fund operations into 2027.
- Net loss for FY2022: $45.2M ($7.8M Q4), compared to $47.5M in FY2021; R&D expenses $26.2M, G&A $18.9M.
- IND-enabling studies for ETX-123 initiated; Phase 1 studies planned for H1 2024; preclinical data at March 2023 symposium.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000095017023006282/0000950170-23-006282-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000095017023006282/elym-20230306.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-006282

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer